To reverse the immunosuppressive tumor microenvironment caused by the loss of the p53 gene in hepatocellular carcinoma (HCC), Xiao et al. developed a CTCE peptide-conjugated CXCR4 (a validated selective target in HCC)-targeted LNP for the efficient encapsulation and HCC-selective delivery of p53 mRNA (Xiao et al.2022). Here, CXCR4 is linked to hepatocellular carcinoma.